Triazavirin-A Novel Effective Antiviral Drug.
Oleg N ChupakhinVladimir L RusinovMikhail V VaraksinEvgeny N UlomskiyKonstantin V SavateevIlya I ButorinWeijie DuZhiyong SunValery N CharushinPublished in: International journal of molecular sciences (2022)
This review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug.
Keyphrases
- clinical trial
- drug induced
- adverse drug
- clinical practice
- healthcare
- electronic health record
- randomized controlled trial
- sars cov
- newly diagnosed
- ejection fraction
- intensive care unit
- liver failure
- systematic review
- big data
- machine learning
- health insurance
- health information
- respiratory failure
- extracorporeal membrane oxygenation
- patient reported outcomes
- replacement therapy